On Jan. 26, the FDA’s vac­cines ad­comm will meet to dis­cuss the fu­ture of Covid-19 boost­er shots and vari­ant strain se­lec­tion mov­ing for­ward, and CBER … ...

A lit­tle more than a month af­ter gain­ing their first OK for their sec­ond CAR-T, Gilead’s Kite is in hot pur­suit of an ex­pand­ed … ...

An­oth­er re­pur­posed drug is en­ter­ing Phase III to see if it pass­es the test against Covid-19.

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

Count Re­gen­eron as the lat­est big bio­phar­ma com­pa­ny to pitch in on find­ing a ther­a­py to com­bat the Wuhan virus.

Long af­ter many an­a­lysts had giv­en Mer­ck’s CETP heart drug anace­trapib up for dead fol­low­ing a slate of ex­pen­sive buri­als for the first three drugs … ...

As Re­gen­eron moves its an­ti­body cock­tail in­to Phase II/III tri­als test­ing REGN-COV2 as a treat­ment for both hos­pi­tal­ized and non-hos­pi­tal­ized pa­tients with Covid-19, the … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The use of flu­dara­bine was fin­gered as a key cul­prit in the deaths of sev­er­al pa­tients tak­ing Juno’s lead CAR-T ther­a­py, but it’s an … ...

House De­moc­rats on Thurs­day fell in line be­hind Speak­er Nan­cy Pelosi’s (D-CA) drug pric­ing bill, vot­ing for its pas­sage 230-192, with two Re­pub­li­cans vot­ing for … ...

When it comes to ex­per­i­men­tal cho­les­terol drugs, all eyes this year are on in­clisir­an, the $9.7 bil­lion RNAi drug No­var­tis hopes will re­place and … ...

For weeks now, an­a­lysts have been fret­ting over the fu­ture of Cel­gene’s $CELG mul­ti­ple scle­ro­sis drug ozan­i­mod. Turned away at the FDA’s ...